Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9922425 | 0.84 | BRD4 (0.37) | BRD4CREBBPP2RY12NLRP3MEN1 | |
| SCHEMBL9923016 | 0.81 | P2RY12 (0.42) | P2RY12 | |
| SCHEMBL12160790 | 0.75 | P2RY12 (0.43) | P2RY12MEN1KMT2ALMNAHTT | |
| SCHEMBL9922839 | 0.73 | P2RY12 (0.35) | P2RY12NLRP3MEN1KMT2A | |
| SCHEMBL9923018 | 0.72 | P2RY12 (0.43) | P2RY12MEN1KMT2AUSP2LMNA | |
| SCHEMBL9922448 | 0.72 | P2RY12 (0.37) | BRD4CREBBPP2RY12MEN1KMT2A | |
| SCHEMBL13638361 | 0.72 | KMT2A (0.50) | BRD4CREBBPMEN1KMT2AUSP2 | |
| SCHEMBL12161524 | 0.71 | PTGER3 (0.37) | P2RY12 | |
| SCHEMBL14113565 | 0.71 | GAA (0.38) | BRD4CREBBPP2RY12NLRP3MEN1 | |
| SCHEMBL9922271 | 0.69 | P2RY12 (0.38) | BRD4CREBBPP2RY12NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | BRD4 3064/4885CREBBP 3041/4885P2RY12 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.